Lab testing firm LabCorp (NYSE:LH) closed out its fiscal year on a down note, with profit growth below historical levels. However, its long-term track record remains intact, and the valuation is reasonable.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Full Year Recap
Revenues advanced 10.8% to $5.5 billion and consisted of a combination of organic growth and acquisitions. Organically, testing volumes increased 1.2% and higher pricing through revenue per requisition, which increased 4.2%. Management detailed that it is in the process of integrating its "Westcliff, Orchid Cellmark and Genzyme Genetics acquisitions."

Operating income fell 3.1% to $948.4 million as LabCorp took more than $160 million in amortization, restructuring and other special charges. Backing out these charges, management estimated that operating income actually improved by 4.8% to $1.1 billion. Net income fell 6.9% to $519.7 million as higher interest expenses ate into the bottom line. This worked out to $5.11 per diluted share. Again, backing out charges, management detailed that earnings advanced 6.5% to $6.37 per diluted share. Free cash flow fell 6.2% to $709.9 million, or approximately $7 per diluted share. (To know more about income statements, read Understanding The Income Statement.)

Outlook
For the coming year, LabCorp expects revenue growth of 2 to 3.5%. Analysts currently project $5.6 billion in sales for 2012. The company projects $6.75 to $7.05 and free cash flow of around $800 million, or $7.85 per diluted share.

The Bottom Line
LabCorp's stock has recovered from the depths of last fall, when it declined to less than $75 per share. However, at $90 per share, the shares are still well below highs of more than $100 in mid-2011. At the current price, they trade at a reasonable forward P/E of 13, and even more reasonable forward free cash flow multiple of only about 11.2.

Despite having largely consolidated the market for independent lab testing firms, LabCorp appears able to continue growing profits at a double digit clip. Over the past five years it has been able to leverage annual sales growth of less than 9% into an annual earnings growth of more than 14%. This easily bests archrival Quest Diagnostics (NYSE:DGX), which has grown sales 6% and profits less than 9% over this same period.

Hospitals, including HCA Holdings (NYSE:HCA) and Health Management Associates (NYSY:HMA), still garner the lion's share of testing volumes throughout the country. Bio-Reference Labs (Nasdaq:BRLI), a lab tester in the eastern United States, has managed to grow sales and profits in excess of 20% and may offer a better combination of growth potential at a reasonable valuation, with a forward P/E of 12. But LabCorp is likely a safer bet given its geographic diversity and strong track record of managing its business for growth. (For additional reading, check out 5 Must-Have Metrics For Value Investors.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Ryan C. Fuhrmann did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  3. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  4. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  5. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  6. Stock Analysis

    The Top 5 Micro Cap Biotechnology Stocks for 2016 (BSTC, OSIR)

    Discover some of the most promising micro-cap biotechnology stocks that investors can consider for their 2016 investment portfolio.
  7. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  8. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  9. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  10. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center